PMID- 36946484
OWN - NLM
STAT- Publisher
LR  - 20240328
IS  - 1875-6190 (Electronic)
IS  - 1570-159X (Print)
IS  - 1570-159X (Linking)
VI  - 22
IP  - 7
DP  - 2023 Mar 22
TI  - REal-World effectIveNess of claDribine for patients with multiple sclerosis: a 
      Sicilian multicentric experience (REWIND study).
PG  - 1271-83
LID - 10.2174/1570159X21666230322140711 [doi]
AB  - BACKGROUND: cladribine tablets is a highly effective option for the treatment of 
      relapsing-remitting multiple sclerosis (RRMS). OBJECTIVE: to evaluate the 
      effectiveness of cladribine in a real-world setting. METHODS: this prospective 
      real-world study consecutively screened all RRMS patients from seven different MS 
      centers in Sicily (Italy), who completed the 2-year treatment course of 
      cladribine tablets in the period between 11th March 2019 and 31st October 2021. 
      Data about Expanded Disability Status Scale (EDSS), relapses, previous 
      treatments, adverse events (AEs) and magnetic resonance imaging (MRI) were 
      collected. Patients who were previously treated with other DMTs were further 
      stratified in moderately active treatment (MAT) and highly active treatment (HAT) 
      patients. RESULTS: a total of 217 patients, (70% women, with mean age of 38.4 +/- 
      11.3 years), were enrolled. Fifty patients (23.0%) were naive to treatment and 
      167 (77%) switched from another disease modifying therapies. After the second 
      year of treatment, about 80% of were EDSS progression free, 88% remained 
      relapse-free at T24, and 48% of patients were MRI activity-free. Kaplan Meier 
      analyses showed significant differences between MT and HAT in terms of time to 
      first clinical relapse (HR: 2.43, IC 1.02 - 5.76; p=0.04), time to the first new 
      T1-gadolinium enhancing lesion (HR: 3.43, IC 1.35 - 8.70; p= 0.009) and time to 
      MRI worsening (HR: 2.42, IC 1.15 - 5.09; p= 0.02). CONCLUSION: this study 
      confirmed that cladribine is an effective treatment for MS, in particular in 
      naive patients and in those who have switched from MATs.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Arena, Sebastiano
AU  - Arena S
AD  - Department "GF Ingrassia" Section of Neurosciences, University of Catania, 
      Catania, Italy.
FAU - Chisari, Clara Grazia
AU  - Chisari CG
AD  - Department "GF Ingrassia" Section of Neurosciences, University of Catania, 
      Catania, Italy.
FAU - Toscano, Simona
AU  - Toscano S
AD  - Department "GF Ingrassia" Section of Neurosciences, University of Catania, 
      Catania, Italy.
FAU - Bucello, Sebastiano
AU  - Bucello S
AD  - Multiple Sclerosis Center- PO Muscatello di Augusta, ASP Siracusa, Siracusa, 
      Italy.
FAU - Grimaldi, Luigi Maria
AU  - Grimaldi LM
AD  - Institute Foundation &G. Giglio&, Multiple Sclerosis Centre, Cefalu-Palermo, 
      Italy.
FAU - Ragonese, Paolo
AU  - Ragonese P
AD  - Department of Biomedicine, Neurosciences and Advanced Diagnostics (BiND), 
      University of Palermo, Palermo, Italy.
FAU - Realmuto, Sabrina
AU  - Realmuto S
AD  - Multiple Sclerosis Centre, Neurology Unit and Stroke Unit, AOOR &Villa 
      Sofia-Cervello&, Palermo, Italy.
FAU - Cottone, Salvatore
AU  - Cottone S
AD  - Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione "Civico Di 
      Cristina e Benfratelli&, Palermo, Italy.
FAU - Maimone, Davide
AU  - Maimone D
AD  - Centro Sclerosi Multipla, UOC Neurologia, ARNAS Garibaldi, Catania, Italy.
FAU - Finocchiaro, Chiara
AU  - Finocchiaro C
AD  - Department "GF Ingrassia" Section of Neurosciences, University of Catania, 
      Catania, Italy.
FAU - Reitano, Paola
AU  - Reitano P
AD  - Department "GF Ingrassia" Section of Neurosciences, University of Catania, 
      Catania, Italy.
FAU - Patti, Francesco
AU  - Patti F
AD  - Department "GF Ingrassia" Section of Neurosciences, University of Catania, 
      Catania, Italy.
LA  - eng
PT  - Journal Article
DEP - 20230322
PL  - United Arab Emirates
TA  - Curr Neuropharmacol
JT  - Current neuropharmacology
JID - 101157239
SB  - IM
PMC - PMC10964096
OTO - NOTNLM
OT  - Multiple sclerosis
OT  - cladribine
OT  - disease modifying therapies
OT  - moderately active treatment.
OT  - switching therapies
COIS- The authors declare no conflict of interest, financial or otherwise.
EDAT- 2023/03/23 06:00
MHDA- 2023/03/23 06:00
PMCR- 2024/08/12
CRDT- 2023/03/22 08:03
PHST- 2022/07/17 00:00 [received]
PHST- 2022/09/29 00:00 [revised]
PHST- 2022/10/27 00:00 [accepted]
PHST- 2024/08/12 00:00 [pmc-release]
PHST- 2023/03/22 08:03 [entrez]
PHST- 2023/03/23 06:00 [pubmed]
PHST- 2023/03/23 06:00 [medline]
AID - CN-EPUB-130323 [pii]
AID - CN-22-1271 [pii]
AID - 10.2174/1570159X21666230322140711 [doi]
PST - aheadofprint
SO  - Curr Neuropharmacol. 2023 Mar 22;22(7):1271-83. doi: 
      10.2174/1570159X21666230322140711.